Acilde Multipl Skleroz: Tanı ve Tedavi
Özet
Multipl Skleroz (MS), santral sinir sisteminin (SSS) en yaygın görülen immün aracılı kronik inflamatuar demiyelinizan hastalığıdır. MS multifaktöryel bir hastalıktır. Temel patolojinin demiyelinizasyon olduğu bilinen ama nedenin kesin olarak açıklanamadığı SSS’nin ilerleyici inflamatuvar hastalığıdır. MS'teki nüksler oldukça değişkendir ve duyusal bozukluk, motor güçsüzlük, görme bozukluğu, dengesizlik, yorgunluk veya bilişsel zorluk içeren bir veya birden fazla nörolojik defisit içerebilir. Temel MS fenotipleri, Relapsing Remitting Multipl Skleroz ve Progresif Relapsing Multipl Skleroz’dur. MS tanısı kesin olarak konulmasını sağlayan testi henüz bulunmamaktadır. Ancak, tanı süresince hastanın klinik öyküsü, fiziksel muayene bulguları, radyolojik görüntüleme sonuçları ve beyin omurilik sıvısı incelenmesi yapılarak birlikte değerlendirilir. McDonald Tanı Kriterleri ile tanı konmaya çalışılmaktadır. Atak tedavisinde ilk tercih intravenöz metil prednizolondur.
Referanslar
Compston A, Coles A. Multipl skleroz. Lancet 2008;372:1502.
Dendrou CA, Fugger L, Friese MA. Multipl sklerozun immünopatolojisi. Nat Rev Immunol 2015;15:545.
Walton C, King R, Rechtman L, Kaye W, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-21.
Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129.
Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: A nationwide cohort study. American Journal of Epidemiology 2005;162:774-8.
Çelik Y, Birgili Ö, Kiyat A, et al. Prevalence of multiple sclerosis in the metropolitan area of Edirne city, Turkey. Balkan Med J. 2011;28(2):193–6.
Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27-40.
Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25–36.
Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1.
Karabudak R. Klinik nöroimmünolojiye giriş. In: Karabudak R. ed, Temel ve Klinik Nöroimmünoloji. Ankara: ADA Basın Yayın Ltd. Şti., 2013:177.
Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis. BMJ 2015;350:1765.
Kemal N, Fak TIP, Tez D, Karaden S. Multı̇pl skleroz hastalarinda hastalik öz yönetı̇mı̇ ve öz yönetı̇mı̇ etkı̇leyen faktörlerı̇n değerlendı̇rı̇lmesı̇ . 2023;
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul;83(3):278–86.
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72(9):800–5.
Lebrun-Frénay C, Okuda DT, Siva A, et al. The radiologically isolated syndrome: revised diagnostic criteria. Brain 2023; 146:3431.
De Stefano N, Giorgio A, Tintoré M, et al. Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Mult Scler 2018; 24:214.
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-69.
Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:6.
Kantarci OH. Phases and Phenotypes of Multiple Sclerosis. Continuum (Minneap Minn) 2019;25:636.
Fambiatos A, Jokubaitis V, Horakova D, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler 2020;26:79.
Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009;73:1996.
Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919.
Stellmann JP, Neuhaus A, Lederer C, et al. Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. PLoS One 2014; 9:e92761.
Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler 2004;10(1):8.
Rice CM, Cottrell D, Wilkins A, Scolding NJ. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry 2013;84:1100.
Khaleeli Z, Ciccarelli O, Mizskiel K, et al. Lesion enhancement diminishes with time in primary progressive multiple sclerosis. Mult Scler 2010;16:317.
Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011;259:659.
Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991;114 (2):1013.
Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 2019;142:1858.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.
Ünal A, Mavioğlu H, Altunrende B. Multiple Skleroz Tanı ve Tedavi Kılavuzu 2018.
Vidal-Jordana A, Montalban X. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects. Neuroimaging Clin N Am. 2017;27(2):195-204.
Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380-90.e2.
Siva A, Işık N, Demirci S, Saip S. Multipl Sklerozda Atak Tedavisi. In: Efendi H, editor. Multiple Sklerozda Tanı ve Tedavi Kılavuzu 2018.
Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;4:CD001331.
Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics: Journal of the American Society for Experimental Neuro Therapeutics 2013;10:97-105.
Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutic 2007;4:618-26.
Beckmann Y, Uzunkopru C. Multipl Skleroz. Istanbul: EMA Tıp Kitabevi Yayıncılık Tic. Ltd. Sti.; 2021.
Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, et al. Aggressive multiple sclerosis (2): Treatment. Mult Scler. 2020;26(9):1352458520924595.
Yamout B, Al-Jumah M, Sahraian MA, et al. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord 2024; 83:105435.
Gedizlioglu M. Nörolojik Hastalıklarda IVIG Kullanım ve Plazma Değişimi. Karabudak R ed. Temel ve Klini Nöroimmünoloji, Ankara: ADA Basın Yayın, Sinca Matbaası 2013;429.
Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39:1143.
